Navigation Links
'Life force' linked to body's ability to withstand stress
Date:6/17/2009

Our ability to withstand stress-related, inflammatory diseases may be associated, not just with our race and sex, but with our personality as well, according to a study published in the July issue of the journal Brain, Behavior and Immunity. Especially in aging women, low levels of the personality trait extraversion may signal that blood levels of a key inflammatory molecule have crossed over a threshold linked to a doubling of risk of death within five years.

An emerging area of medical science examines the mind-body connection, and how personality and stress contribute to disease in the aging body. Long-term exposure to hormones released by the brains of people under stress, for instance, takes a toll on organs. Like any injury, this brings a reaction from the body's immune system, including the release of immune chemicals that trigger inflammation in an attempt to begin the healing process. The same process goes too far as part of diseases from rheumatoid arthritis to Alzheimer's disease to atherosclerosis, where inflammation contributes to clogged arteries, heart attacks and strokes.

The current study found that that extroverts, and in particular those high "dispositional activity" or engagement in life, have dramatically lower levels of the inflammatory chemical interleukin 6 (IL-6). Swiss psychiatrist Carl Jung defined extroverts as focused on the world around them and most happy when active and surrounded by people. Introverts looked inward and were shy.

The definitions of extraversion and other personality traits were refined by American psychologist Gordon Allport beginning in the 1930s. He reviewed all adjectives in the dictionary used to describe personality, and attempted to group them into clusters. Over the next several decades, researchers statistically analyzed these dictionary terms and discovered that they tended to cluster into five general dimensions: extraversion vs. introversion, emotional stability vs.
'/>"/>

Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. The Presidents Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners
2. Lifelike Robot Provides Innovative Rehabilitation Treatment for Patients
3. SunGard Named Top Life and Health Solution Provider in 2009 Insurers Choice Technology Ranking
4. Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association
5. Sepsis Treatment Offers Lifesaving Potential
6. Lifestyle May Counter Blood Pressure Genes
7. CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
8. All Seven Members of RBC Life Sciences Board of Directors Were Re-Elected During the Companys 2009 Annual Shareholders Meeting
9. Have a Purpose in Life? You Might Live Longer
10. Thomson Reuters Partners with Research4Life to Bring Scientific Research Information Resources to Developing Countries Around the World
11. LifeWorks Mentoring to Become Program of L.A. Gay & Lesbian Center
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 1Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 2Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 3American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 55925 1American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 55925 2Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 1Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 2Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 3
Other Medicine Technology:Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 2Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 3Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 4Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 5Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4